Loading quotes...

Forecast

The analysts' average price target is €20.50 (+166.58%). The median is €20.50 (+166.58%).

Buy	3
Hold	0
Sell	0

News Go to news feed

Daxor completes registered capital raise of about $8.1 million

Daxor sold 765,958 common shares in a registered direct placement at $11.75 each and generated net proceeds of approximately $8.14 million after fees. The placement was made under a shelf registration the SEC declared effective on January 20, 2026; Lake Street Capital Markets acted as placement agent. The stock is currently trading slightly above the issue price at $12.28; market capitalization is around $61.21 million. » More on de.investing.com
Daxor jumps 40% after FDA approval for new blood volume analysis device

Shares of Daxor Corporation surged 40% after the company received 510(k) clearance from the US Food and Drug Administration (FDA) for its new blood volume analysis device. The compact handheld device provides faster and more accurate results for fluid management in various medical conditions and was developed on behalf of the US Department of Defense. Studies show significant clinical benefits and cost savings from using Daxor's technology. » More on de.investing.com
Daxor confirms board and auditor, presents progress on blood volume analyzers

At its annual general meeting, Daxor elected six board members and confirmed Bush & Associates, CPA, as its auditor. The company submitted its new blood volume analyzer to the FDA and presented research demonstrating the superiority of its technology in treating heart failure. Daxor continues to collaborate with the US Department of Defense and the NIH on innovative healthcare solutions. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, DAXOR CORP. DL -,01 has already paid €0.0378 in dividends. The last payout was in July 2025.

Financials

In the last quarter, DAXOR CORP. DL -,01 had revenue of €20.17k and net profit of -€2.9m

(EUR)	June 2026	YoY
Revenue	20.17k	-
Gross profit	-52.86k	-
Net profit	-2.9m	-
EBITDA	-2.9m	-

Fundamentals

Metric	Value
Market capitalization	€45.28m
Number of shares	5.84m
52-week high/low	€13.16 - €7.49
Dividends	No
Beta	0.26
P/E ratio	7.07
PEG ratio	0.03
P/B ratio	0.84
P/S ratio	327.98

Company profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.